Physician profile
Shafi M Khalid
NPI 1750343760
$2,631.91
in general payments reported to CMS, 2019-2025
24 companies · $651 in 2025
The $651 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $840 · 2020: $307 · 2021: $171 · 2022: $95.64 · 2023: $250 · 2024: $317 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,218.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $824.29 | 2019-2025 | Wavewriter Alpha Prime 16, Na |
| Abbott Laboratories | $304.17 | 2019-2025 | Octrode, Proclaim, Prodigy |
| Nevro Corp. | $275.89 | 2019-2024 | Senza |
| Lilly USA, LLC | $222.28 | 2019-2024 | Reyvow, Emgality |
| Biodelivery Sciences International, INC. | $156.86 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $94.58 | 2020-2024 | Ajovy |
| Pfizer INC. | $74.27 | 2019-2023 | |
| Indivior INC. | $73.49 | 2019-2022 | |
| Spr Therapeutics, INC | $73.31 | 2024 | Sprint Pns System |
| Pacira Therapeutics, INC. | $71.37 | 2019 | |
| Orexo US, INC. | $70.89 | 2019-2020 | |
| Lundbeck LLC | $59.55 | 2025 | Vyepti |
| Si-Bone, INC. | $58.46 | 2019-2025 | |
| Arbor Pharmaceuticals, INC. | $44.72 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $38.39 | 2019-2023 | Ztlido |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $37.56 | 2019-2021 | |
| Abbvie INC. | $34.68 | 2023 | |
| Allergan, INC. | $24.21 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $18.98 | 2025 | |
| Assertio Therapeutics, INC. | $18.61 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.81 | 2019 | |
| Metacel Pharmaceuticals LLC | $13.58 | 2023 | Ozobax |
| Fidia Pharma USA INC. | $13.17 | 2024 | Hymovis |
| Kaleo, INC. | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shafi Khalid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.